



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/988,285	11/19/2001	Johannes Henricus Matthias Schellens	Q67353	8475
2292	7590	01/14/2004		
BIRCH STEWART KOLASCH & BIRCH			EXAMINER	
PO BOX 747			PARAS JR, PETER	
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
			1632	

DATE MAILED: 01/14/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.	09/988,285	Applicant(s)	SCHELLENS ET AL.
Examiner	Peter Paras, Jr.	Art Unit	1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 14 October 2003.
2a) This action is FINAL. 2b) This action is non-final.
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-22 and 30-34 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) Claim(s) _____ is/are allowed.
6) Claim(s) _____ is/are rejected.
7) Claim(s) _____ is/are objected to.
8) Claim(s) 1-22 and 30-34 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

- 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) The translation of the foreign language provisional application has been received.
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). _____.
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. 6) Other: _____

DETAILED ACTION

Applicant's election without traverse of Group I, claims 1-22, in the response received on 10/14/03 is acknowledged.

Claims 25-26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the response received on 10/14/03.

New claims 30-34 have been added and correspond to the elected invention. Claims 23-29 have been cancelled. Claims 1-22 and 30-34 are pending and are under current consideration.

Upon further consideration further restriction of claims 1-22 and 30-34 is necessary. See below.

Election/Restrictions

Claims 1-22 and 30-34 are generic to a plurality of disclosed patentably distinct species of inhibitors of BCRP:

- A. acridine derivatives
- B. quinoline derivatives
- C. isoquinoline derivatives
- D. combination of A, B, and C

E. GF120918

F. XR 9051

G. XR 9576

Patentably distinct methods for increasing systemic exposure of cells to an orally administered pharmaceutically active compound comprising administering an inhibitor of BCRP are encompassed by the claims. A specific member of a species of BCRP inhibitor should be elected. If combination of A, B, and C is elected, a specific combination should be elected as each combination appears to be distinct from the others.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, from one of groups A-G, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Claims 1-22 and 30-34 are generic to a plurality of disclosed patentably distinct species of bioenhancer:

A. mycotoxin

B. fumitremorgin C

Patentably distinct methods for increasing systemic exposure of cells to an orally administered pharmaceutically active compound comprising administering a bioenhancer are encompassed by the claims. A specific member of a species of bioenhancer should be elected. If A is elected, a specific mycotoxin other than fumitremorgin C should be elected as each combination appears to be distinct from the others.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, from one of groups A-B, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Claims 1-22 and 30-34 are generic to a plurality of disclosed patentably distinct species of pharmaceutically active compound:

- A. indolizino-quinoline derivatives
- B. camptothecin derivatives
- C. anthraquinone derivatives

D. quinazoline derivatives

E. GG211

F. DX8951f

G. BNP1350

H. 9-aminocamptothecin

I. 9-nitrocamptothecin

J. CPT11

K. any metabolite of A-J

L. SN38

Patentably distinct methods for increasing systemic exposure of cells to an orally administered pharmaceutically active compound are encompassed by the claims. A specific member of a species of pharmaceutically active compound should be elected. If K is elected, a specific metabolite of A-J, other than SN38, should be elected as each metabolite appears to be distinct from the others.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, from one of groups A-L, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Peter Paras, Jr., whose telephone number is 703-308-8340. The examiner can normally be reached Monday-Friday from 8:30 to 4:30 (Eastern time). The examiner is scheduled to move a new office, on 1/13/2004, having a new telephone number as follows: 571-272-0732.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at 703-305-4051. Papers related to this application may be submitted by facsimile transmission. Papers should be faxed via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Official Fax Center number is (703) 872-9306.

Inquiries of a general nature or relating to the status of the application should be directed to Dianiece Jacobs whose telephone number is (703) 305-3388.

Peter Paras, Jr.

**PETER PARAS
PATENT EXAMINER**

Art Unit 1632

